PainChek Ltd (ASX:PCK) Shares Extend Gains: What's Happening?

Sonal Goyal

03 November 2026 03:09 PM AEDT

PainChek Ltd (ASX:PCK) Shares Extend Gains: What's Happening?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

PainChek shares rose 11.94% to $0.075 in the 3 November 2026 trading session, while the S&P/ASX 200 gained 0.14%.
Unaudited quarterly customer Revenue rose 12.9% quarter on quarter to $1.210 million, and 42.4% year on year.
Quarter-end cash was $4.269 million, after a net operating cash outflow of $1.714 million.

During the Trading session on 3 November 2026, PainChek Ltd (ASX:PCK) shares rose 11.94% to $0.075. The S&P/ASX 200 (ASX:XJO) was up 0.14%, or 12.50 points, at 8,869.00 at 2:42 pm (GMT+11) on the same day. PainChek develops a pain assessment platform used in aged care. Its quarterly activities report, dated 28 October 2026, covers the September 2026 quarter.

Revenue and recurring income

Unaudited quarterly customer revenue rose 12.9% quarter on quarter to $1.210 million and was up 42.4% year on year. Activated licences reached 91,323, and activated annual Recurring Revenue reached $4.514 million, both up 1.2% quarter on quarter.

Customers and assessments

Customer retention improved to 90%, and activated customer sites reached 2,076. Cumulative assessments reached 24.49 million. Bolton Clarke, Anglicare, BaptistCare and Dovehaven each exceeded one million assessments.

US and UK contracts

In the US, a two-site Silverado paid pilot covers 203 licences, within an opportunity of up to 2,500 licences across 31 sites. After quarter end, Sabra expanded to 23 contracted sites covering 808 licences. Hallmark Luxury Care Homes signed a contract for about 1,800 licences across 23 homes in England and Wales.

Cash and costs

Customer receipts were $1.045 million, and quarter-end cash was $4.269 million. The net operating outflow of $1.714 million included $1.136 million of government grants and tax incentives. Cost-saving initiatives are in progress.

Sector context

The S&P/ASX 200 gained 0.14% during the session. The company's report links its growth to aged care providers adopting its assessment tool in Australia, the US and the UK.

Risks

The company reported a net operating cash outflow for the quarter. Further Silverado rollout depends on the pilot evaluation and additional agreements. The report also notes changes across leadership, operations and the board.

What lies ahead

The company expects the Silverado pilot to be evaluated before further rollout, and cost-saving initiatives are continuing.

Final Word

The quarter showed higher revenue and new contracts alongside a continuing operating cash outflow.

FAQs

Q: How did PainChek shares trade on 3 November 2026?

A: During the trading session, shares rose 11.94% to $0.075, while the S&P/ASX 200 gained 0.14%.

Q: How much revenue did PainChek report?

A: Unaudited quarterly customer revenue was $1.210 million, up 12.9% quarter on quarter.

Q: How much cash did it have?

A: Quarter-end cash was $4.269 million after a net operating outflow of $1.714 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.